Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CCRN Stock Forecast 2026-2027
$9.62
Current Price
$309.25M
Market Cap
Buy 2
Hold 7
Sell 0
Wall St Analyst Ratings
Distance to CCRN Price Targets
+45.5%
To High Target of $14.00
+9.1%
To Median Target of $10.50
+4.0%
To Low Target of $10.00
CCRN Price Momentum
-2.0%
1 Week Change
+19.1%
1 Month Change
-38.3%
1 Year Change
+18.8%
Year-to-Date Change
-40.5%
From 52W High of $16.18
+29.5%
From 52W Low of $7.43
📊 TOP ANALYST CALLS
Did CCRN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Cross Country is one of their latest high-conviction picks.
Latest CCRN Stock Price Targets & Analyst Predictions
Based on our analysis of 15 Wall Street analysts, CCRN has a neutral consensus with a median price target of $10.50 (ranging from $10.00 to $14.00). The overall analyst rating is Buy (6.7/10). Currently trading at $9.62, the median forecast implies a 9.1% upside. This outlook is supported by 2 Buy, 7 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Bill Sutherland at Benchmark, projecting a 45.5% upside. Conversely, the most conservative target is provided by Tobey Sommer at Truist Securities, suggesting a 4.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CCRN Analyst Ratings
2
Buy
7
Hold
0
Sell
CCRN Price Target Range
Low
$10.00
Average
$10.50
High
$14.00
Current: $9.62
Latest CCRN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CCRN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 5, 2026 | Benchmark | Bill Sutherland | Buy | Upgrade | $14.00 |
| Feb 3, 2026 | Wedbush | Michael Piccolo | Neutral | Initiates | $11.00 |
| Dec 9, 2025 | UBS | A.J. Rice | Neutral | Maintains | $9.00 |
| Jun 17, 2025 | Barrington Research | Kevin Steinke | Market Perform | Maintains | $18.61 |
| May 13, 2025 | UBS | A.J. Rice | Neutral | Maintains | $16.50 |
| Mar 14, 2025 | Barrington Research | Kevin Steinke | Market Perform | Maintains | $18.61 |
| Feb 6, 2025 | JMP Securities | Constantine Davides | Market Perform | Reiterates | $N/A |
| Dec 10, 2024 | Barrington Research | Kevin Steinke | Market Perform | Downgrade | $N/A |
| Dec 5, 2024 | Truist Securities | Tobey Sommer | Hold | Maintains | $18.61 |
| Nov 7, 2024 | Benchmark | Bill Sutherland | Buy | Maintains | $18.00 |
| Oct 21, 2024 | Truist Securities | Tobey Sommer | Hold | Maintains | $15.00 |
| Aug 8, 2024 | Barrington Research | Kevin Steinke | Outperform | Maintains | $19.00 |
| Aug 1, 2024 | Truist Securities | Tobey Sommer | Hold | Maintains | $17.00 |
| May 6, 2024 | Barrington Research | Kevin Steinke | Outperform | Maintains | $21.00 |
| May 2, 2024 | Benchmark | Bill Sutherland | Buy | Maintains | $19.00 |
| Feb 27, 2024 | Barrington Research | Kevin Steinke | Outperform | Maintains | $24.00 |
| Feb 22, 2024 | Benchmark | Bill Sutherland | Buy | Maintains | $21.00 |
| Feb 22, 2024 | Truist Securities | Tobey Sommer | Hold | Maintains | $16.00 |
| Dec 6, 2023 | JMP Securities | Constantine Davides | Market Perform | Initiates | $N/A |
| Nov 30, 2023 | UBS | A.J. Rice | Neutral | Initiates | $22.00 |
Cross Country Healthcare Inc. (CCRN) Competitors
The following stocks are similar to Cross Country based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CCRN
Cross Country Healthcare
mkt cap
321.70M
Cross Country Healthcare Inc. (CCRN) Financial Data
Cross Country Healthcare Inc. has a market capitalization of $309.25M with a P/E ratio of 48.3x. The company generates $1.05B in trailing twelve-month revenue with a -9.0% profit margin.
Revenue growth is -23.6% quarter-over-quarter, while maintaining an operating margin of -0.6% and return on equity of -25.6%.
Valuation Metrics
Market Cap
$309.25M
Enterprise Value
$204.49M
P/E Ratio
48.3x
PEG Ratio
0.0x
Price/Sales
0.3x
Growth & Margins
Revenue Growth (YoY)
-23.6%
Gross Margin
N/A
Operating Margin
-0.6%
Net Margin
-9.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+35.0%
Current Ratio
3.8x
Debt/Equity
0.7x
ROE
-25.6%
ROA
+0.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Cross Country Healthcare Inc. (CCRN) Business Model
About Cross Country Healthcare Inc.
What They Do
Provides staffing solutions for healthcare sector.
Business Model
The company generates revenue by offering a range of staffing services, including travel nurse and allied health staffing, per diem and permanent placement, as well as workforce management solutions to healthcare facilities. By addressing staffing shortages and enhancing operational efficiency for hospitals, Cross Country Healthcare ensures a steady stream of income from its diverse client base.
Additional Information
Established in Boca Raton, Florida, Cross Country Healthcare leverages its extensive industry expertise and vast network to meet the critical demand for healthcare professionals, thereby improving healthcare accessibility and patient care across various settings.
Company Information
Sector
Healthcare
Industry
Medical Care Facilities
Employees
9,605
CEO
Mr. Kevin Cronin Clark
Country
United States
IPO Year
2001
Website
www.crosscountry.comCross Country Healthcare Inc. (CCRN) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Cross Country (CCRN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Cross Country (CCRN) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Mar 05, 2026
By Zacks Equity Research
Fundamental Analysis
Cross Country Healthcare (CCRN) Reports Q4 Loss, Lags Revenue Estimates
Cross Country (CCRN) delivered earnings and revenue surprises of -300.00% and -6.14%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Mar 04, 2026
By Zacks Equity Research
Tale of the Tape
5 Broker-Liked Stocks to Monitor Amid the Ongoing Volatility
Broker upgrades and rising earnings estimates highlight stocks like ARW, GOLD, CCRN, AMN and PENN amid geopolitical tensions and tech-sector volatility.
Mar 04, 2026
By Maharathi Basu
Analyst Blog
Latest News
Quick Summary
Cross Country and Open Hearts for Orphans have partnered to enhance support for families and communities, aiming to improve outcomes for vulnerable children.
Why It Matters
The partnership between Cross Country and Open Hearts for Orphans may enhance brand reputation, attract socially responsible investors, and potentially lead to increased market value through positive community impact.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Cross Country Healthcare, Inc. (CCRN) has released its Q4 2025 earnings call transcript, detailing its financial performance and key business updates for investors.
Why It Matters
The Q4 2025 earnings call for Cross Country Healthcare, Inc. provides insights into financial performance and future outlook, impacting stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Cross Country Healthcare (Nasdaq: CCRN) reported Q4 2025 revenue of $236.8M, down 24% year-over-year and 5% sequentially. Full-year 2025 revenue was $1.05B, a 22% decline from 2024.
Why It Matters
Cross Country Healthcare's significant revenue decline in Q4 2025 and full year signals potential operational challenges, impacting future growth and investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Cross Country Healthcare (CCRN) reported a quarterly loss of $0.06 per share, missing the Zacks Consensus Estimate of $0.03, compared to earnings of $0.04 per share last year.
Why It Matters
CCRN's larger-than-expected quarterly loss indicates potential operational issues, which could negatively impact investor confidence and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Cross Country (CCRN) reported its Q4 2025 financial results, highlighting key metrics against Wall Street estimates and year-ago figures. Investors may find these comparisons significant.
Why It Matters
Cross Country's performance relative to Wall Street estimates and previous year values can indicate growth trends and market positioning, impacting investor confidence and stock valuation.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Broker upgrades and increased earnings estimates are boosting stocks such as ARW, GOLD, CCRN, AMN, and PENN, amid geopolitical tensions and volatility in the tech sector.
Why It Matters
Broker upgrades and rising earnings estimates signal potential growth for ARW, GOLD, CCRN, AMN, and PENN, attracting investor interest despite market volatility and geopolitical risks.
Source: Zacks Investment Research
Market Sentiment:
Negative
Frequently Asked Questions About CCRN Stock
What is Cross Country Healthcare Inc.'s (CCRN) stock forecast for 2026?
Based on our analysis of 15 Wall Street analysts, Cross Country Healthcare Inc. (CCRN) has a median price target of $10.50. The highest price target is $14.00 and the lowest is $10.00.
Is CCRN stock a good investment in 2026?
According to current analyst ratings, CCRN has 2 Buy ratings, 7 Hold ratings, and 0 Sell ratings. The stock is currently trading at $9.62. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CCRN stock?
Wall Street analysts predict CCRN stock could reach $10.50 in the next 12 months. This represents a 9.1% increase from the current price of $9.62. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cross Country Healthcare Inc.'s business model?
The company generates revenue by offering a range of staffing services, including travel nurse and allied health staffing, per diem and permanent placement, as well as workforce management solutions to healthcare facilities. By addressing staffing shortages and enhancing operational efficiency for hospitals, Cross Country Healthcare ensures a steady stream of income from its diverse client base.
What is the highest forecasted price for CCRN Cross Country Healthcare Inc.?
The highest price target for CCRN is $14.00 from Bill Sutherland at Benchmark, which represents a 45.5% increase from the current price of $9.62.
What is the lowest forecasted price for CCRN Cross Country Healthcare Inc.?
The lowest price target for CCRN is $10.00 from Tobey Sommer at Truist Securities, which represents a 4.0% increase from the current price of $9.62.
What is the overall CCRN consensus from analysts for Cross Country Healthcare Inc.?
The overall analyst consensus for CCRN is neutral. Out of 15 Wall Street analysts, 2 rate it as Buy, 7 as Hold, and 0 as Sell, with a median price target of $10.50.
How accurate are CCRN stock price projections?
Stock price projections, including those for Cross Country Healthcare Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 13, 2026 10:14 PM UTC